Rubius Therapeutics (STU:5RT) Float Percentage Of Total Shares Outstanding : 43.67% (As of Sep. 25, 2024)

View and export this data going back to 2019. Start your Free Trial

What is Rubius Therapeutics Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Rubius Therapeutics's float shares is 39.52 Mil. Rubius Therapeutics's total shares outstanding is 90.48 Mil. Rubius Therapeutics's float percentage of total shares outstanding is 43.67%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Rubius Therapeutics's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Rubius Therapeutics's Institutional Ownership is 0.58%.

Rubius Therapeutics Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Rubius Therapeutics's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	39.52	/	90.48
	=	43.67%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rubius Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rubius Therapeutics Inc (STU:5RT) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

124 Washington Street, Suite 101, Foxborough, MA, USA, 02035

Website

https://www.rubiustx.com

Rubius Therapeutics Inc develops red cell therapeutics (RCTs) for the treatment of patients with rare diseases, cancer, and autoimmune diseases.

Rubius Therapeutics Headlines

No Headlines